Aetion

Aetion

Software solutions for real-world evidence analysis

About Aetion

Simplify's Rating
Why Aetion is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Differentiation

Industries

AI & Machine Learning

Healthcare

Company Size

201-500

Company Stage

Series C

Total Funding

$203.6M

Headquarters

New York City, New York

Founded

2012

Overview

Aetion creates software solutions that help life sciences companies, regulators, and purchasers make informed decisions using real-world evidence (RWE). Their platform analyzes real-world data to provide insights into the effectiveness and safety of medical innovations, enabling clients to generate clinical insights that were previously difficult to obtain. Aetion differentiates itself by focusing on maximizing the return on investment for real-world data, offering quick insights that facilitate critical decision-making. The company's goal is to expedite patient care by equipping life sciences companies with the necessary tools for data-driven decisions.

Simplify Jobs

Simplify's Take

What believers are saying

  • Datavant's acquisition of Aetion could enhance its market reach and innovation capacity.
  • NEC's investment supports Aetion's collaboration in utilizing Japanese health records for drug development.
  • The Barcelona technology hub expansion leverages European talent for innovative RWE solutions.

What critics are saying

  • Datavant's acquisition may lead to strategic shifts impacting Aetion's business model.
  • Integration into AWS Marketplace could increase competition from other software vendors.
  • Barcelona hub expansion may lead to increased operational costs and management challenges.

What makes Aetion unique

  • Aetion's platform uses real-world data to provide regulatory-grade evidence for decision-making.
  • The company collaborates with major pharmaceutical firms to enhance drug development processes.
  • Aetion's integration with AWS Marketplace simplifies access to its analytics solutions.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$203.6M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.
Series C Funding Comparison
Above Average

Industry standards

$50M
$50M
Medium
$62M
SeatGeek
$100M
Oura
$110M
Aetion

Benefits

Medical, dental, & vision insurance

Free membership to OneMedical

FSA

4% 401(k) match

Commuter benefits for parking & transit

Unlimited PTO

Paid parental leave

Wellness stipend

Company activities

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↓ -1%

2 year growth

↓ -2%
Endpoints News
May 15th, 2025
Datavant Acquires Aetion, Expands Team

Datavant is acquiring Aetion, a competitor in the real-world data sector, as reported exclusively by Endpoints News. This acquisition will lead to Datavant doubling its life sciences team. Further details are expected to be announced by Datavant on Thursday.

PR Newswire
Mar 31st, 2025
Aetion Launches Aetion® Evidence Platform Availability In Aws Marketplace, Accelerating Real-World Evidence Benefits For Its Customers

Aetion's industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering organizations to unlock the full potential of their data and achieve measurable impactNEW YORK, March 31, 2025 /PRNewswire/ -- Aetion , the global leader in real-world evidence (RWE) technology and analytics, today announced the availability of its Aetion® Evidence Platform (AEP) in Amazon Web Services (AWS) Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on AWS. This launch removes implementation barriers, simplifies procurement and enables life sciences organizations, payers and regulators to harness scalable, cloud-based evidence generation with the security and reliability of AWS.AEP empowers organizations to analyze real-world data (RWD) to generate transparent, reproducible and regulatory-grade evidence for decision-making in drug development, market access, policy and pricing. By leveraging AWS Marketplace, Aetion streamlines access to its platform and reliable, fit-for-purpose solutions tailored to meet each organization's specific objectives, as well as accelerating time-to-insights and ensuring compliance with global regulatory standards.Aetion relies on AWS as its core infrastructure, leveraging services such as Amazon Bedrock to power its artificial intelligence and machine learning (AI/ML)-driven capabilities in order to unlock hidden insights about patient populations and translate scientific intent to results. These technologies enhance AEP's ability to process complex RWD at scale, enabling sophisticated hypothesis generation and analysis automation for evidence generation."The availability of AEP in AWS Marketplace underscores our commitment to providing scalable, high-impact solutions that help organizations make real-world data work for them," said Jay Podence, senior vice president of Commercial Partnerships at Aetion. "By integrating with AWS, we offer our new and existing customers a seamless path to deploy and scale real-world evidence studies with enhanced efficiency and security. This is the first step in our vision to expand our collaboration with AWS to bring more value to our customers

PR Times
Feb 19th, 2025
NEC invests in Aetion for RWD/RWE collaboration

NEC's CVC fund, NEC Orchestrating Future Fund, has invested in Aetion, Inc., a U.S. company providing a medical data analysis platform. This investment aims to enhance collaboration in utilizing real-world data (RWD) and real-world evidence (RWE) for drug development. Aetion's platform, Aetion Evidence Platform, is used globally by pharmaceutical companies and healthcare organizations to improve decision-making. NEC and Aetion will explore synergies to streamline drug development processes.

PR Newswire
Feb 18th, 2025
NEC Invests in Aetion for RWD Collaboration

NEC Orchestrating Future Fund (NOFF) has invested in Aetion, a leader in real-world evidence technology. NEC and Aetion will collaborate to use Japanese electronic health records for drug development via Aetion's Substantiate® application. This partnership aims to enhance drug development efficiency and regulatory pathways. Aetion's platform uses AI and privacy-preserving techniques to transform real-world data into evidence, supporting personalized medicine and next-gen healthcare.

CityBiz
Sep 13th, 2024
Aetion Appoints Kevin Riley as President

Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the appointment of Kevin Riley as president.

Recently Posted Jobs

Sign up to get curated job recommendations

Aetion is Hiring for 13 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
We update Aetion's jobs every few hours, so check again soon! Browse all jobs →